UNSPSC 51262914: Propranolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H21NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8A3652H1V, chemically known as 2-propanol, 1- (isopropylamino)-3-(1-naphthyloxy)-, hydrochloride but more generally known as propranolol hydrochloride, which bears US NIH Compound Identifier 4946. European Medicines Agency schedules Propranolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04091MIG.

UNSPSC 51262914 Propranolol hydrochloride (Commodity) shows a mismatch between its nominal scope and recent state and local procurement activity. The code names a specific pharmaceutical—propranolol hydrochloride, a beta-blocker used to treat hypertension and cardiac conditions—yet the single recent opportunity tagged to this code solicits naloxone and drug deactivation systems, products unrelated to propranolol. The source contains no evidence of state and local governments actually procuring propranolol hydrochloride or other medications under this code tier in the recent window.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking to purchase 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carries a two-year initial term with one-year renewal option and requires vendors to meet E-Verify compliance, drug-free workplace certification, and standard commercial insurance. The mismatch between the code's pharmaceutical focus and the naloxone procurement suggests either miscoding in the source or a data quality issue; the code does not reflect genuine current market activity for propranolol procurement at the state and local level.